Ception Begins Phase II/III Trial For Eosinophilic Esophagitis Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Designated an orphan drug by FDA, reslizumab is targeted toward pediatric patients.
You may also be interested in...
Gastroenterology Endpoints To Get Four-Day Series Of FDA Workshops
One day each will be devoted to eosinophilic esophagitis, pediatric and adult inflammatory bowel disease, and parenteral nutrition-associated liver disease, Sept. 19, 20, 21 and 24, in that order.
Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says
Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.
Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says
Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.